1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. EQT AB (publ)
  6. News
  7. Summary
    EQT   SE0012853455

EQT AB (PUBL)

(EQT)
  Report
Delayed Nasdaq Stockholm  -  11:29 2022-08-12 am EDT
267.70 SEK   -0.59%
08/12Certara Down 15% After Announcing Stock Sale by Shareholders
DJ
08/07Shell, BP, Others Weigh Offers for Denmark's Nature Energy
MT
07/28Morrison & Co, EQT Reportedly in Running for PRP Diagnostic Imaging
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EQT's Galderma announces positive trial results on skin drug

06/22/2022 | 02:00am EDT
FILE PHOTO: A Swiss flag is pictured on the Federal Palace in Bern

BERLIN, June 22 (Reuters) - EQT's Galderma on Wednesday said its injectable drug nemolizumab helped patients suffering from the rare skin disease prurigo nodularis in a trial, potentially underpinning the owner's ambitions to list the skincare firm.

In a late-stage trial, Galderma's drug was shown to remove lesions and ease itch in some patients. Itch is a chronic symptom of the potentially debilitating skin disease.

Sources told Reuters in May that EQT is delaying listing plans for Galderma as market volatility and recession fears in Europe cool investor appetite for what could be Switzerland's biggest flotation in more than two decades.

The listing could happen in the autumn or early next year depending on market conditions, the sources said at the time.

Japan's Maruho Co. Ltd is also working on a prurigo nodularis treatment while French drugmaker Sanofi is running trials to get its bestselling eczema drug Dupixent also approved for the disease. (Reporting by Ludwig Burger, Writing by Miranda Murray)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
BANK OF AMERICA CORPORATION 1.09% 36.3 Delayed Quote.-18.41%
BNP PARIBAS 1.77% 50.43 Real-time Quote.-17.02%
CITIGROUP INC. 0.70% 54.38 Delayed Quote.-9.95%
CREDIT SUISSE GROUP AG 1.78% 5.482 Delayed Quote.-38.21%
EQT AB (PUBL) -0.59% 267.7 Delayed Quote.-45.70%
MORGAN STANLEY 1.62% 91.66 Delayed Quote.-6.62%
MSCI SINGAPORE (GDTR) -0.17% 5868.22 Real-time Quote.-6.53%
NOVARTIS AG -1.16% 80.1 Delayed Quote.-0.22%
SANOFI 0.84% 85.46 Real-time Quote.-3.52%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) 1.32% 61.55 Delayed Quote.-19.11%
All news about EQT AB (PUBL)
08/12Certara Down 15% After Announcing Stock Sale by Shareholders
DJ
08/07Shell, BP, Others Weigh Offers for Denmark's Nature Energy
MT
07/28Morrison & Co, EQT Reportedly in Running for PRP Diagnostic Imaging
CI
07/25Rebelle Jumps 8% on $31 Million Takeover Bid from EQT-backed Vinted
MT
07/15Investor AB Reports Negative Total Shareholder Return of 17% in 2Q
DJ
07/14European Stocks Fall on European Commission's Gloomy Summer Economic Forecast
MT
07/14EQT's Interim Profit Misses Estimates as Increasingly Challenging Market Tempers Invest..
MT
07/14EQT's H1 Profit Falls As Investment Activity Slows
MT
07/14TRANSCRIPT : EQT AB, H1 2022 Earnings Call, Jul 14, 2022
CI
07/14EQT's H1 Profit Falls As Investment Activity Slows
MT
More news
Analyst Recommendations on EQT AB (PUBL)
More recommendations
Financials
Sales 2021 1 461 M 1 498 M 1 498 M
Net income 2021 796 M 816 M 816 M
Net cash 2021 628 M 644 M 644 M
P/E ratio 2021 31,7x
Yield 2021 1,48%
Capitalization 25 459 M 26 104 M 26 104 M
EV / Sales 2021 17,0x
EV / Sales 2022 15,5x
Nbr of Employees 1 356
Free-Float 37,3%
Chart EQT AB (PUBL)
Duration : Period :
EQT AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EQT AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 25,58 €
Average target price 32,12 €
Spread / Average Target 25,6%
EPS Revisions
Managers and Directors
Christian Otto Sinding Chief Executive Officer & Managing Partner
Kim Henriksson Chief Financial Officer
Yngve Conni Jonsson Director
Christina Drews Chief Operating Officer
Gordon Robert Halyburton Orr Independent Director
Sector and Competitors
1st jan.Capi. (M$)
EQT AB (PUBL)-45.70%26 104
PARTNERS GROUP HOLDING AG-31.70%28 880
PETERSHILL PARTNERS PLC-14.21%3 285
BRIDGEPOINT GROUP PLC-42.96%2 807
GOLUB CAPITAL BDC, INC.-7.19%2 449
RATOS AB (PUBL)-16.84%1 575